Conditions: Epithelial Ovarian Cancer Extraovarian Peritoneal Cancer Fallopian Tube Carcinoma
Keywords: Epithelial Ovarian Cancer FIGO (International Fed of Gyn and Ob)Stage III or Stage IV Extraovarian Peritoneal Cancer Fallopian Tube Carcinoma Failing
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 19
Healthy volunteers: no

Brief summary:
This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.

Detailed description:
This is a non-randomized, single-arm, Phase II trial. Selected patients with advanced-stage epithelial ovarian cancers who have no reasonable chance of cure using standard regimens, or who will not receive such regimens (due to contraindication or intolerance) are eligible. Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.

Arms:
arm 1: Administration of Ontak IV for treatment of epithelial ovarian cancer

Interventions: intervention 1: Ontak
Intervention descriptions: intervention 1: Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.

Protocol document: